Medifast (MED) Tops Q2 EPS by 44c ; Offers Guidance

Medifast (NYSE: MED) reported Q2 EPS of $0.22, $0.44 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $105.6 million versus the consensus estimate of $96.1 million.

GUIDANCE:

Medifast sees Q3 2025 EPS of ($0.60)-$0.00, versus the consensus of ($0.30). Medifast sees Q3 2025 revenue of $70-90 million, versus the consensus of $93.8 million.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• GameStop CEO Cohen buys 1.15M shares
• Wabtec signs $700M rail services deal for Guinea mining project
• Cematrix wins $8.8M in new contracts, bringing YTD total to $43.2M